There are 2789 resources available
86P - The predictive values of EPHA3 mutations for response to immune checkpoint inhibitors in solid tumors
Presenter: Zhongxing Bing
Session: ePoster Display
232P - Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)
Presenter: Yoon Sim Yap
Session: ePoster Display
174P - Better survival associated with successful vitamin D supplementation in non-metastatic breast cancer survivors
Presenter: Elif Isbilen
Session: ePoster Display
139P - HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
Presenter: Francesco Cognetti
Session: ePoster Display
236P - Real-world comparative effectiveness of palbociclib plus letrozole vs letrozole in older patients with metastatic breast cancer
Presenter: Hope Rugo
Session: ePoster Display
Resources:
Abstract
Slides
179P - Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study
Presenter: Chengzheng Wang
Session: ePoster Display
180P - Relapse pattern after neoadjuvant treatment in early breast cancer
Presenter: Ariadna Gasol Cudos
Session: ePoster Display